Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages

Chronic lymphocytic leukemia (CLL) has a variable clinical evolution, with some patients living treatment-free for decades while others require therapy shortly after diagnosis. In a consecutive series of 217 CLL patients, molecular biomarkers with prognostic value (IGHV status, TP53 mutations, and c...

Full description

Saved in:
Bibliographic Details
Published inDiagnostics (Basel) Vol. 12; no. 8; p. 1802
Main Authors Suárez-Cabrera, Alexia, Fiallo-Suárez, Dolly Viviana, Stuckey, Ruth, Uroz-de la Iglesia, Marta Luna, Florido, Yanira, Lemes-Castellano, Angelina, Perera-Álvarez, Miguel Ángel, Luzardo-Henríquez, Hugo, de la Nuez, Haridian, Fernández-Caldas, Paula, de la Iglesia, Silvia, Gómez-Casares, María Teresa, Bilbao-Sieyro, Cristina
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 25.07.2022
MDPI
Subjects
Age
Asymptomatic
biomarkers
Chromosomes
Chronic lymphocytic leukemia
Diagnosis
Genetic aspects
Genetic screening
Leukemia
Medical prognosis
Methods
molecular diagnostics
Multivariate analysis
Mutation
patient outcome
Patients
Prognosis
Survival analysis
Variables
Spain
Online AccessGet full text

Cover

More Information
Summary:Chronic lymphocytic leukemia (CLL) has a variable clinical evolution, with some patients living treatment-free for decades while others require therapy shortly after diagnosis. In a consecutive series of 217 CLL patients, molecular biomarkers with prognostic value (IGHV status, TP53 mutations, and cytogenetics), whose analysis is recommended prior to treatment start, were studied at diagnosis. Multivariate analyses identified prognostic variables for overall survival (OS) and time to first treatment (TTFT) and validated the CLL-IPI and IPS-E variables for all or early-stage patients (Rai 0–2/Binet A), respectively. Unmutated IGHV was associated with shorter OS and TTFT, even for early-stage patients. Lymphocyte count was not statistically significant for TTFT of early-stage patients in multivariate analysis. Our results validate the prognostic value of IGHV mutational status at diagnosis for OS and TTFT, including for early stages. Our findings suggest a role for molecular and mutational analysis at diagnosis in future prospective studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics12081802